{"id":"W3190145293","doi":"10.1016/j.ygyno.2021.07.016","title":"Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial","year":2021,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Adverse effect; Discontinuation; Internal medicine; Neutropenia; Nausea; Vomiting; Placebo; Oncology; Anemia; Ovarian cancer; Surgery; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001721687,0.0006870725,0.001198792,0.0001706476,0.0002650882,0.000684243,0.0004706097,0.0007838338,0.003134283],"category_scores_gemma":[0.001299956,0.0002825858,0.00128824,0.0002446953,0.0003902813,0.0005080057,0.0002496725,0.001505979,0.0003819557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005138678,"about_ca_system_score_gemma":0.0008028376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002402286,"about_ca_topic_score_gemma":0.0007851761,"domain_scores_codex":[0.9994726,0.000332599,0.00002841106,0.00007095558,0.00004541286,0.00005013996],"domain_scores_gemma":[0.9990337,0.0002107581,0.0003737274,0.00005759662,0.00004386913,0.0002803965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.932693,0.004163238,0.007619136,0.0005588941,0.00139767,0.0001395842,0.00007511233,0.000706353,0.005717917,0.00009099087,0.002008219,0.04482983],"study_design_scores_gemma":[0.873185,0.1049697,0.01659383,0.00007369113,0.0007068226,0.0003143005,0.00002882491,0.0009080157,0.001078865,0.0002148339,0.00190588,0.00002015785],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916101,0.004672866,0.0003143888,0.00057846,0.0001115076,0.0007037487,0.0008117862,0.00005069572,0.001146496],"genre_scores_gemma":[0.9929305,0.00174544,0.0005898099,0.0007581417,0.0002064069,0.001207101,0.001583264,0.00001404894,0.0009651527],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003134283,"threshold_uncertainty_score":0.01048523,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01888383592380004,"score_gpt":0.3414188082779412,"score_spread":0.3225349723541411,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}